
DIABMET-FMT: lean-donor fecal transplant improved insulin resistance in type 2 diabetes
The shared description of the DIABMET-FMT randomized trial says repeated fecal microbiota transplant capsules from lean, metabolically healthy donors improved insulin sensitivity, microbiome diversity and short-chain fatty acid production in adults with type 2 diabetes, without diet, drug or exercise changes. The poster sees it as evidence that the microbiome contributes to diabetes in some people. The details come from the post only and could not be verified here.


